News & Events

≪ Back to All News & Events

July 2010

Lawrence Bruder joins Noxilizer as President & Chief Executive Officer

Lawrence Bruder joins Noxilizer as President & Chief Executive Officer

Noxilizer, Inc., a developer of next generation gas sterilization technology for hospitals and life science companies, announced the appointment of Lawrence Bruder as President & Chief Executive Officer.

“Larry brings over 25 years of leadership and operational experience in large and small life science companies. His successful track record in achieving value creating milestones, attracting investors and leading venture-backed companies made him an extremely attractive candidate,” said Lars Hanan, member, Noxilizer Board of Directors and Co-founder and Managing Partner at BroadOak Capital Partners.

Larry’s professional experience includes leadership positions at: Becton Dickinson, Applied Biosystems, Leica, Olympus, and Guava Technologies. Most recently he was President and CEO of venture-backed Guava Technologies, which was sold to Millipore Biosciences in 2009. Most of his experience prior to Guava was at Becton Dickinson, where he held a number of significant operational and leadership positions over a 10-year period. His responsibilities in both companies included the clinical and regulatory aspects of 510(k) submittals to the FDA for medical devices, significant commercial interaction with pharmaceutical companies, and high level business development transactional activity; all of these being a critical part of Noxilizer’s needs.

“I’m very excited to join the team at Noxilizer, as the core NO2 sterilant technology will enable gentle, safe but effective low temperature sterilization of sensitive medical devices, such as pre-filled syringes, bioresorbable polymers and flexible endoscopes. The sterilization of these devices represents a huge global market opportunity for Noxilizer and I look forward to commercializing this capability within the hospital and life science marketplace, “said Larry Bruder.

Mr. Bruder holds a BS from Rochester Institute of Technology and Master of Management in Marketing & Economics from the Kellogg Graduate School at Northwestern University.

About Noxilzer:
Noxilizer is pioneering the development of a unique and superior sterilization technology that will revolutionize two major sterilization markets — hospitals and life science manufacturing. In hospitals, Noxilizer is developing a system especially for the sensitive high-tech equipment increasingly used in minimally invasive surgical procedures. In the life science market, the development of next generation therapies and medical devices for cardiovascular disease, cancer, and diabetes is constrained by current sterilization technologies which destroy chemical, biologic, and mechanical properties of many products. Noxilizer’s room-temperature system has shown great potential to be an enabling technology for a wide range of products, including antibodies, proteins, drug-device combination products, pre-filled syringes, bioresorbable polymers, nanoparticles and implants.

Advantages include: more gentle and lethal sterilization, safe for workers and the ability to sterilize long lumens used in minimally invasive surgery and other procedures.

Noxilizer is committed to providing innovative solutions for healthcare professionals and their patients. The company was founded in 2004 and is privately held. Noxilizer is located at the University of Maryland Baltimore County Technology Center in Baltimore, MD.

Maura O. Kahn

Vice President of Business Development & Marketing
Noxilizer, Inc.
1450 South Rolling Road
Baltimore, MD 21227
(443) 543-5783